HC Wainwright Issues Negative Estimate for DRUG Earnings
Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of Bright Minds Biosciences in a ...
Q1 Earnings Forecast for RCUS Issued By HC Wainwright
Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Arcus Biosciences in a report issued on ...
H.C. Wainwright says SEC plan to dismiss suit lifts ‘major overhang’ on Coinbase
H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...
H.C. Wainwright Sticks to Its Hold Rating for Biotricity (BTCY)
H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Biotricity (BTCY – Research Report) today. The company’s shares closed yesterday ...
Cleanspark Unusual Options Activity
Looking at options history for Cleanspark CLSK we detected 29 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish ...
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief ...
Balchem projects strong 2025 growth amid new product launches and robust segment performance
Discover Balchem's record-breaking Q4 2024 performance with $240M in sales and innovation-driven growth in nutrition segments.
kalkinemedia2d
HC Wainwright Predicts Lower Earnings for Bausch + Lomb
Highlights,Adjusted Q1 2025 EPS projections for Bausch + Lomb as analysts slightly reduce expectations.,Diverse analyst ...